AKT1 and psoriasis: Multi-omics identifies the activation of the PI3 K/AKT/mTOR and JAK-STAT pathway in 76% of psoriasis lesions; FABP5 overexpression (1.8-fold vs. normal skin) is a potential therapeutic target.